个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共10条记录   New Developments in Pharmaceutical Treatments for Cystic Fibrosis [作者：Grasemann, H,期刊：Current Pharmaceutical Design, 页码：613-613 , 文章类型： Editorial Material，,卷期：2012年18-5] New Therapies in Cystic Fibrosis [作者：Ratjen, F; Grasemann, H,期刊：Current Pharmaceutical Design, 页码：614-627 , 文章类型： Review，,卷期：2012年18-5] Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that lead to abnormalities in transepithelial ion transport in the airways of affected patients. Lung disease ... Identification and Validation of Hits from High Throughput Screens for CFTR Modulators [作者：Pasyk, S; Molinski, S; Yu, W; Eckford, PDW; Bear, CE,期刊：Current Pharmaceutical Design, 页码：628-641 , 文章类型： Review，,卷期：2012年18-5] These are exciting times with the appearance of small molecule compounds in clinical trials which target the basic defects caused by mutation in the CFTR gene. This progress was enabled by years of basic research probing... Progress in Gene and Cell Therapy for Cystic Fibrosis Lung Disease [作者：Griesenbach, U; Alton, EWFW,期刊：Current Pharmaceutical Design, 页码：642-662 , 文章类型： Review，,卷期：2012年18-5] Although the development of gene therapy for cystic fibrosis (CF) was high priority for many groups in academia and industry in the first 10 to 15 years after cloning the gene, more recently active research into CF gene ... Early In Vivo Testing to Assess New Therapeutic Interventions in CF Patients [作者：Gonska, T,期刊：Current Pharmaceutical Design, 页码：663-673 , 文章类型： Review，,卷期：2012年18-5] New therapeutic strategies are targeting correction of the basic defect in cystic fibrosis (CF) disease. In fact, completion of the first successful clinical drug trials now signals the start of a new era in CF therapy. ... Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis [作者：Dorfman, R,期刊：Current Pharmaceutical Design, 页码：674-682 , 文章类型： Review，,卷期：2012年18-5] Since the discovery of the CFTR gene mutations which cause cystic fibrosis (CF) in 1989 the average life expectancy of CF patients has almost doubled and now exceeds 37 years. The advances in molecular diagnostics and me... New Developments in Inhaled Antibiotics for the Treatment of Pseudomonas aeruginosa [作者：Hofmann, T,期刊：Current Pharmaceutical Design, 页码：683-695 , 文章类型： Review，,卷期：2012年18-5] The field of inhaled antibiotics that target Pseudomonas aeruginosa infections has made substantial contributions to the health, disease management, and life expectancies of individuals with cystic fibrosis (CF) over the... New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas [作者：Waters, V,期刊：Current Pharmaceutical Design, 页码：696-725 , 文章类型： Review，,卷期：2012年18-5] The development of antimicrobial treatments for respiratory pathogens in cystic fibrosis (CF) has been an integral component to the increased survival of CF patients over the past fifty years. Despite significant treatme... Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis [作者：Grasemann, H; Ratjen, F,期刊：Current Pharmaceutical Design, 页码：726-736 , 文章类型： Review，,卷期：2012年18-5] The concentrations of nitric oxide are decreased in airways of patients with cystic fibrosis. The reasons for this nitric oxide deficiency are incompletely understood but may include reduced production from nitric oxide ... New Developments In Treatment After Lung Transplantation [作者：Benden, C; Danziger-Isakov, L; Faro, A,期刊：Current Pharmaceutical Design, 页码：737-746 , 文章类型： Review，,卷期：2012年18-5] Lung transplantation has evolved as an accepted therapy in selected adults and children with end-stage lung disease. Outcomes following lung transplantation have improved in the recent era with a 5-year survival of >70% ...